comparemela.com

Latest Breaking News On - Meters biopharma inc view - Page 1 : comparemela.com

9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced

Bethany sensenigAl medwarMark sirgoMeters biopharma inc viewInvestor relations corporate communicationsMeters biopharma incDrug administrationJohn temperatoChief executive officerChief financial officerAnnual reportQuarterly reportsInvestor relationsInc viewGefallene big techs

9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023

RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided

United statesLas vegasJohn temperatoAl medwarClinical developmentMeters biopharma inc viewMeters biopharma incInvestor relations corporate communicationsChief executive officerShort bowel syndromePractice conferenceInvestigational new drugDigestive disease weekAnnual reportQuarterly reportsInvestor relations

9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity

RALEIGH, NC / ACCESSWIRE / April 5, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced

Al medwarJohn temperatoMeters biopharma incMeters biopharma inc viewInvestor relations corporate communicationsDrug administrationInvestigational new drugChief executive officerAnnual reportQuarterly reportsInvestor relationsInc view

9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

RALEIGH, NC / ACCESSWIRE / March 7, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced

Dennis riedlAl medwarJohn temperatoMeters biopharma inc viewMeters biopharma incInvestor relations corporate communicationsChief executive officerAnnual healthcareAnnual reportQuarterly reportsInvestor relationsCorporate communicationsInc view

9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

Study design incorporates two primary endpoints to evaluate the efficacy of vurolenatide in short bowel syndrome with or without parenteral support dependenceStudy design allows for the assessment of the

United statesAl medwarJohn temperatoPatrickh griffinVeronica eamesNational institute of diabetesMeters biopharma inc viewDrug administrationMeters biopharma incLifesci communicationsInvestor relations corporate communicationsNorth americaChief medical officerNew drug applicationReview boardChief executive

vimarsana © 2020. All Rights Reserved.